Relay Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The zovegalisib/atirmociclib/fulvestrant triplet showed a 44% ORR and favorable tolerability in heavily pretreated metastatic breast cancer patients, supporting advancement to a phase III frontline trial targeting PI3Kα-mutated, endocrine-sensitive patients. Regulatory discussions and trial initiation are planned for early next year.
-
The company is advancing a mutant-selective PI3K alpha inhibitor, zovegalisib, in metastatic breast cancer and vascular anomalies, with key data readouts expected this year and in 2026. Strong cash reserves support operations through 2029, and the pipeline is positioned for multiple late-stage catalysts.
-
Key updates include imminent data releases for zovegalisib in breast cancer and vascular anomalies, with a focus on demonstrating differentiated efficacy and safety. Enrollment in pivotal trials is progressing, and the company is targeting large, underserved patient populations with potential for accelerated approval.
Fiscal Year 2025
-
Execution of phase III trials for a PI3K alpha mutant selective inhibitor is progressing, with strong confidence in achieving superior PFS over current standards. Competitive landscape analysis highlights efficacy and safety differentiation, while pipeline expansion into vascular malformations and other indications is supported by robust financial resources.
-
RLY-2608 is advancing as a selective PI3Kα inhibitor with strong efficacy and tolerability in breast cancer and vascular malformations. The program is well-funded, strategically positioned against competitors, and targets significant commercial opportunities in both oncology and rare diseases.
-
RLY-2608, a PI3K mutant-selective inhibitor, is showing strong efficacy and safety in metastatic breast cancer and is being advanced in vascular malformations, both representing multi-billion dollar opportunities. The AI-enabled platform drives productivity, with several programs in the clinic.
-
RLY-2608 shows strong efficacy and safety in PIK3CA-mutated breast cancer, with a phase III trial underway and promising results in key subpopulations. The commercial opportunity is significant, and expansion into vascular malformations and other cancers is planned.
-
The company is advancing its PI3K alpha selective inhibitor RLY-2608 into a pivotal phase 3 trial for breast cancer, supported by strong clinical data and a robust cash runway. Expansion into vascular malformations and other programs is ongoing, with a focus on execution and commercialization.
-
RLY-2608 shows strong efficacy and a favorable safety profile in PI3Kα-mutant breast cancer, with pivotal trials planned and a strategy to broaden patient access. Expansion into vascular malformations leverages similar advantages, with a flexible regulatory approach for potential accelerated approval.
-
RLY-2608 shows strong efficacy in PI3Kα-mutated breast cancer, with pivotal Phase III enrollment set for mid-year and a focus on durable results at ASCO. Vascular malformation studies are underway, and a robust cash position supports operations through 2029.
-
Capital is now focused on advancing the PI3Kα program for breast cancer, with phase III trials underway and mature data showing strong efficacy versus benchmarks. Additional studies target vascular malformations and preclinical assets, supported by a robust cash position and strategic flexibility.
-
Entering 2025 with a strong cash position, the focus is on executing a pivotal RLY-2608 trial in breast cancer, supported by robust clinical data and a lean portfolio. RLY-2608 shows superior efficacy and safety versus competitors, with multiple catalysts fully funded.
-
Industry resilience has improved post-COVID, with no current operational impacts from macro changes. RLY-2608's new dosing regimen is FDA-approved, offering improved safety and supporting pivotal trials, while competitive positioning remains strong with a significant lead over rivals.
-
Updated clinical data for RLY-2608 show strong efficacy and safety, with a pivotal phase III trial set to compare it head-to-head with capivasertib. The company is advancing triplet combinations, expanding into vascular malformations, and managing resources to prioritize key milestones.
-
Four major clinical programs will launch in 2025, with a strong focus on breast cancer and the pivotal phase 3 trial of RLY-2608, which has shown superior efficacy and tolerability. Additional programs in vascular malformations, NRAS-driven tumors, and Fabry disease are set to expand the clinical pipeline.
Fiscal Year 2024
-
RLY-2608, a selective PI3K alpha inhibitor, showed a median PFS of 9.2 months (11.4 months in second-line) and a favorable safety profile in heavily pretreated breast cancer patients, outperforming current standards. A pivotal trial and new studies in vascular malformations are planned for 2025.
-
Breast cancer therapy is advancing toward all-oral, targeted combinations, with RLY-2608 showing superior efficacy and safety in second-line HR+/HER2- patients. Its clean profile supports broad use and combinability, setting it apart from less selective competitors.
-
Promising data for RLY-2608 in PI3K alpha mutated breast cancer show strong efficacy and tolerability, with a pivotal Phase III trial in preparation. Combination strategies and competitive differentiation are central, supported by robust financing and plans for expanded indications.
-
Significant pipeline progress includes new Fabry and NRAS programs, strong 2608 data in breast cancer, and expansion into vascular malformations. Phase 3 trial for 2608 is prioritized, with robust financials supporting development through 2028.
-
RLY-2608 shows strong efficacy and safety in breast cancer, with pivotal trials planned and expansion into vascular malformations and triplet combinations underway. The pipeline includes a near-term NDA for FGFR2, a Fabry disease program targeting broader mutations, and an NRAS inhibitor.
-
RLY-2608 plus fulvestrant showed a 9.2-month median PFS and strong safety in heavily pretreated, PIK3CA-mutated breast cancer, outperforming current standards. A pivotal Phase III trial versus capivasertib is planned for 2025, with additional studies in first-line and other indications underway.
-
The platform integrates advanced tools to target precision oncology, genetic diseases, and vascular malformations, with major data readouts for RLY-2608 in breast cancer and updates on FGFR2, Fabry, and NRAS programs expected over the next year. Strategic collaborations and regulatory milestones are set to expand clinical impact.
-
Three new programs were announced, expanding the pipeline to 11 candidates across oncology and genetic diseases. Key updates include a pivotal trial for RLY-2608 in breast cancer, new clinical collaborations, and first-in-class therapies for Fabry disease and NRAS-mutant cancers, all supported by a strong financial position.